Health Canada released a number of reports over the summer:
- Annual Health Product Highlights for 2021, which provides an overview of new health products, including drugs and medical devices, that Health Canada approved for sale in Canada in 2021, as well as other 2021 highlights.
- The Pharmaceutical Drugs Directorate (PDD; formerly TPD), the Biologic and Radiopharmaceutical Drugs Directorate (BRDD) and the Natural and Non-Prescription Health Products Directorate (NNHPD) have released their Drug Submission Performance Annual Reports for Fiscal Year 2021-2022. The reports contain information regarding pharmaceutical, biologic and radiopharmaceutical, and non-prescription and disinfectant drug submission review activity over five consecutive fiscal years (April 1 to March 31) from 2017-2018 to 2021-2022.
- The Office of Patented Medicines and Liaison Statistical Report 2021/2022 provides an overview of Health Canada’s administration of the Patented Medicines (Notice of Compliance) Regulations, the data protection regime and Certificates of Supplementary Protection. The Report includes information regarding trends in listing on the Patent Register and the Register of Innovative Drugs, and applications and outcomes for Certificates of Supplementary Protection, as well as related court activity for each topic.
In the meantime, should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Health Canada releases new guidance document on clinical evidence requirements for medical devices
On November 15, 2022, Health Canada released a new guidance document, “ Guidance on clinical evidence requirements for medical devices.” In it, Health Canada provides guidance on clinical evidence req...Read More -
Federal Court rejects pre-trial determination of a question of law about the nature of the section 8 but-for world
As previously reported, the Federal Court found Janssen’s Canadian Patent No. 2,661,422 (422 patent) – which relates to treatment of prostate cancer in humans by co-administration of abiraterone aceta...Read More -
Federal Court of Appeal restores Minister of Health’s decision to grant RUZURGI NOC despite FIRDAPSE data protection
The Federal Court found that subsection C.08.004.1(3) of the Food and Drug Regulations applied to prevent the Minister from issuing an NOC in view of the data protection granted to FIRDAPSE, a drug co...Read More